Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Complix N.V. logo — Complix is a biopharmaceutical company leading the way in th...

Complix N.V.

Complix is a biopharmaceutical company leading the way in the use of biologics for challenging disease targets.

Founded 2008 Belgium Belgium 5 employees Grant Total: $21.90M Biotechnology, Health Care

General Information

Company Name Complix N.V.
Founded Year 2008
Location Belgium Belgium
Employees 5
Industries Biotechnology, Health Care
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with Complix N.V.. To contact Complix N.V., visit complix.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Complix N.V. compare?

A PDF of Complix N.V. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Complix N.V. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Complix N.V.

Complix N.V. is a biopharmaceutical company based in Belgium that is pioneering the use of biologics for challenging disease targets. The company was founded in 2008 and is dedicated to the discovery and development of protein therapeutics using its proprietary alphabody™ technology. Alphabodies, which are robust and versatile protein scaffolds unrelated to immunoglobulins, are inspired by naturally occurring motives. Complix has developed the proprietary Cell Penetrating Alphabody (CPAB) technology, allowing it to access a broad range of intracellular disease-related targets that are considered "intractable" by currently available drug formats, such as antibodies and small molecules. The company's most recent investment was a €1.20M grant investment received on 07 September 2020. This investment was made by Agentschap Innoveren & Ondernemen. Complix's focus on addressing challenging disease targets with its innovative biologic technology makes it an attractive prospect for potential venture capital investment. Its unique approach to developing protein therapeutics positions the company as a potentially disruptive force in the biotechnology and health care industries.

Business keywords: biopharmaceutical company, biologics, protein therapeutics, alphabody technology, cell penetrating technology, intracellular disease, drug discovery, protein scaffolds, non-injectable routes, disease targets, therapeutic proteins, biotech, pharmaceutical research, innovation, technology platforms

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Grant €1.20M 1
Agentschap Innoveren & Ondernemen
07 Sep 2020
Grant €500.00K 1
Agentschap Innoveren & Ondernemen
14 Dec 2017
Series B €12.00M 8
Limburgse Reconversie Maatschappij GIMV Andera Partner
Limburgse Reconversie Maatschappij, GIMV +6
26 Jun 2013
Series A €2.00M -
02 Feb 2011
Series A $6.20M -
10 Jun 2010

Complix N.V. Alternatives & Competitors

View All Alternatives
Complix N.V. vs
Degron Therapeutics
Degron Therapeutics United States

Aims to become a global leader in the discovery and development of molecular glue degraders

Series A
25 employees
Biotechnology, Health Care
Complix N.V. vs
MEDIBIOFARMA SL
MEDIBIOFARMA SL Spain

To make disease-modifying treatments available to patients with serious or life-threatening conditio...

Venture round
8 employees
Biotechnology, Health Care
Complix N.V. vs
InSingulo AB
InSingulo AB Sweden

The right environment for drug discovery

Seed
11 employees
Biotechnology, Health Care
View all alternatives

FAQ About Complix N.V.

Complix is a biopharmaceutical company leading the way in the use of biologics for challenging disease targets.
Complix N.V. was founded in 2008.
Complix N.V. is headquartered in Belgium.
Complix N.V. operates in Biotechnology and Health Care. Its work centres on biopharmaceutical company, biologics, protein therapeutics and alphabody technology.
Complix N.V. has approximately 5 employees.
Complix N.V. has completed 5 funding rounds, raising a total of $21.90M. The latest funding stage is Grant.
Top alternatives and competitors to Complix N.V. include Degron Therapeutics, MEDIBIOFARMA SL, InSingulo AB, Flexus Biosciences, Sitryx. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Complix N.V. and Degron Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Complix N.V., https://bouncewatch.com/company/complix-nv, updated 25 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes